NCT00688454已完成不适用
C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 3,392
- 主要终点
- LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin
研究概览
简要总结
The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with hypercholesteremia who was never treated with statins before
- •Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR
排除标准
- 未提供
结局指标
主要结局
LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin
时间窗: 3 visits within 10 weeks
次要结局
- Tolerability of CRESTOR-therapy(3 visits within 10 weeks)
研究者
相似试验
已完成
2 期
Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal DiseaseHyperlipidemiaNCT00296400AstraZeneca237
已完成
2 期
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal DiseaseDiabetes MellitusNCT00296374AstraZeneca353
终止
4 期
Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive PatientsAtherosclerosisHIV InfectionsNCT00673582University of British Columbia250
终止
4 期
The Effect of Lipitor on Aortic StenosisAortic Valve StenosisNCT00590135The Cleveland Clinic59
已完成
不适用
Evaluation of Crestor® (Rosuvastatin) in Daily PracticeHypercholesterolemiaNCT00837083AstraZeneca602